Quality management in hospitals: analysis of the prescribing practice of cardiovascular medicines by Stoimenova, Assena et al.
www.wjpps.com           Vol 3, Issue 3, 2014.      
                           
 
93 
 
Stoimenova   et al.                   World Journal of Pharmacy and Pharmaceutical Sciences 
 
 
 
QUALITY MANAGEMENT IN HOSPITALS: ANALYSIS OF THE 
PRESCRIBING PRACTICE OF CARDIOVASCULAR MEDICINES 
 
Assena Stoimenova1*, Alexandra Savova1, Svetla Georgieva2, Bistra Angelovska3, 
Guenka Petrova1 
 
1Department of Social pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical 
University - Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria 
2Alexandrovska University Hospital, 1 St. Georgi Sofiiski Str, 1431 Sofia, Bulgaria 
3University in Shtip, Faculty of Medical Sciences, Department of Pharmacy, Shtip, FYROM 
 
ABSTRACT  
The goal of this study is to analyse the prescribing practice and risk of 
drug related errors in a Cardiology clinic of University Hospital. Semi-
structured open-ended interview aiming to reveal the risk of potential 
errors was performed with physicians, nurses, pharmacists, and 
hospital managers. Observational analysis of 915 prescriptions, 
prescribed by the physicians in two cardiology departments was 
conducted. Prescribing practice was evaluated by the means of its 
complexity, frequency of prescribing of particular pharmacology 
groups, and the related costs. Most often gaps detected in prescribing 
and dispensing of medicinal products were associated with missing or 
incorrect dosages, and unspecified quantity. Our analysis showed  
preference to combination therapies. Monotherapy was given only in 24.82% of the acute 
cases treated and in 24% of the cases treated in the internal ward. Two medicinal products 
were identified in 24.48% of the prescriptions (intensive care unit) and in 19.24% of the 
prescriptions from the internal ward. The most prescribed medicinal products were bisoprolol 
and glyceryl trinitrate in a combination. Approximately 45% of the patients were prescribed 
up to 3 medicinal products.The increase of therapy complexity leads to increase of 
probability for drug-drug interactions and nearly 30% of prescriptions were evaluated as 
potentially risky for interactions. The relative shares of potentially risky combinations vary 
from 4% to 32% out of all prescriptions reviewed. The likelihood of drug-related problems in 
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the observed Cardiology clinic was determined as high but no practice for recording of ADRs 
was found in place.  
 
Key words: prescribing practice, cardiovascular medicines, cardiology, drug utilization, 
medication errors. 
 
INTRODUCTION  
Drug prescribing is a major part of the practice of medicine [1,2]. Drug utilisation studies are a 
necessary tool for assessing prescribing habits in hospitals and for recognizing areas for 
improvement of prescribing practice in these facilities [3-5]. Moreover, some studies suggested 
that  systematic measurement of drug utilization is a key element of drug prescribing 
improvement and cost control strategies [6-8]. Hospitalized patients are usually prescribed 
multiple drug treatment (especially in intensive care unit) which is often associated with 
potentially harmful drug interactions [9-11]. Potential drug related problems (DRP) for 
hospitalized patients are therefore a cause of concern [11,12]. Drug related problems are 
classified into two categories: medication errors (MEs) and adverse drug reactions (ADRs) 
[11,13,14] MEs could occur at five levels: drug selection, prescribing, dispensing, 
administration, and therapeutic monitoring. ADRs include unintended clinical effects after 
administration of a drug. Drug related problems can result in decreased quality of life, 
morbidity or mortality, as well as in increased cost of therapy [14,15].   
 
The goal of this study is to analyse the prescribing practice and risk of drug related errors in 
the Cardiology clinic of University Hospital. 
 
The research questions discussed in the study are the following: 
 What is the possibility and reasons of DRP occurring in the observed Cardiology clinic? 
 Are there differences in the prescribing practice, cost and risk of drug related problems 
occurring in both departments of the Cardiology clinic?  
 
MATERIALS AND METHODS  
A study consisting of interview, retrospective prescribing analysis, analysis of drug 
interactions and likelihood of errors.  
 
To assess the sources of DRP a structured interview with pre-set questions in a free form was 
performed with five physicians, ten nurses, three hospital pharmacists, as well as with the 
hospital director. Health professionals were asked to describe their duties related to 
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prescription and dispensing of medicinal products, to identify the main difficulties and 
opportunities to improve the control over the inter-hospital life cycle of medicinal products. 
In addition they were asked to identify any potential sources of medication errors. 
 
The possibility of DRP was analysed after a retrospective review of medication records of 
915 patients, admitted in the two wards of the Cardiology Clinic of the University’ Hospital. 
286 prescriptions from the intensive care cardiology unit and another 629 prescriptions from 
the internal cardiology ward were examined. The prescriptions were classified according to 
their complexity, pharmacology groups of prescribed medicines, prices and pharmacotherapy 
course costs. Differences in the prescribing practice and cost of therapy were statistically 
tested with z-test for proportions differences in prescribing and t-test for cost differences. 
 
The risk for drug interactions and likelihood of errors was evaluated through comparison of 
selected prescription combinations with literature evidences for development of risk 
interactions. The common prescriptions, errors and possible sources of errors were analyzed 
and their distribution in both departments was evaluated with t-test.  
 
RESULTS  
Interview results  
The interview performed with health professionals revealed that the most often sources of 
medication errors in the prescribing and dispensing practice, were the following:  
 missing dosage regimes; 
 unspecified dosage form if more than one form was available; 
 unspecified or wrong quantity of packs/vials etc.; 
 wrong dosages. 
 
Those errors were not recorded because the hospital policy normally requires contact with the 
physician or nurse and clarification of any missing or wrong data. The hospital pharmacy 
computer program can screen the dosage regimes and prescription errors and correct them 
before the delivery to the relevant ward. The dispensing errors are very rare because due to 
the additional control performed by the hospital pharmacy managers and nurses together 
before the delivery. During the observed one year period only one error was documented. 
Due to similarity in the packages’ design of two medicinal products, a wrong package was 
dispensed by the hospital pharmacists and the error was corrected after check by the 
pharmacy manager and responsible nurse. 
www.wjpps.com           Vol 3, Issue 3, 2014.      
                           
 
96 
 
Stoimenova   et al.                   World Journal of Pharmacy and Pharmaceutical Sciences 
Prescribing practice and costs of treatment  
The analysis of prescribing practice showed preference to combination therapy. Monotherapy 
was given in 24.82% of the acute cases and in 24% of the cases treated in the internal 
cardiology ward. Two medicinal products were prescribed for 24.48% of the patients in the 
intensive care unit and for 19.24% of the patients in the internal ward (Table 1, Figure 1).  
 
Approx. 45% of the patients were prescribed up to 3 medicinal products. The rest 55% who 
take more than 3 medicines were exposed to a high risk of DRP. In the internal department, 
1.43% of patients were prescribed ten medicinal products, which were administered 
concomitantly (Figure 1). Although the differences in the complexity of therapy exist they 
were not statistically significant among both departments (p> 0.05).  
 
Table 1. Pharmacotherapy prescribed in both wards in value and percentage  
 
 Number of prescribed medicinal products 
Ward 1 medicine 
2 
medicines 
3 
medicines 
4 
medicines 
5 
medicines 
6 
medicines 
7 
medicines 
10 
medicines 
Intensive 
care 71 70 54 37 35 14 5 0 
Internal 
ward 151 121 85 95 89 53 26 9 
 
The most prescribed medicines in both departments belong to the group of anticoagulants 
(26%), followed by diuretics. Bisoprolol and acid acetylsalicylic were the most prescribed in 
the intensive care ward and they were present in almost all combination prescriptions. As part 
of ditherapy, glyceryl trinitrate was often prescribed (Table 2). 
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Figure 1. Distribution of patients according to the number of medicines prescribed 
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The most prescribed pharmacology groups were anticoagulants (26% in both wards), 
followed by diuretics 21% and 24% respectively (Table 2). The frequency of prescribing of 
ACE inhibitors differed and it was 18% and 10% in the intensive care unit and internal ward 
respectively. 19% of prescriptions were prescribed by the intensive unit staff and 14% from 
internal ward contained beta-blockers and 11% and 6% respectively, vasodilatators (Table 
2).  
Table 2. Prescribing of cardiovascular medicines in both wards  
 
 
Almost all of the pharmacology groups acting on CV system were found prescribed and 
anticoagulants were at a highest risk of occurrence of DRPs. Although differences in 
prescribing of CV medicinal products exist in both wards, they were not statistically 
significant (Table 2).  
 
Table 3. Costs of therapy per patient 
 
Average daily costs per therapy in the cardiology clinic (in Bulgarian leva) 
Complexity of 
therapy 
Intensive care 
ward 
Internal care 
ward t-test analysis 
Monotherapy 1.67 0.88 
p>0.05 
Ditherapy 2.02 3.12 
3 medicines 1.90 2.03 
4 medicines 2.16 2.35 
5 medicines 3.62 3.38 
6 medicines 5.70 3.96 
7 medicines 9.48 6.15 
10 medicines - 5.30 
 
CV pharmacology 
group 
Cardiology clinic/ 
Intensive care ward 
Cardiology clinic/ 
Internal ward 
z-test 
analysis 
Antiarrhythmics 3.10% 3.62% 
p> 0.05 
Anticoagulants 26.00% 26.07% 
АСЕ-inhibitors 17.55% 10.21% 
Beta-blockers 13.86% 18.59% 
Vasodilatators 6.05% 11.16% 
Diuretics 23.90% 21.38% 
Antilypidemics 8.26% 8.02% 
Calcium channel 
blockers 1.33% 0.95% 
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Mean cost of therapy was 1.70 Euro per patient (SD1.5291) in the intensive care ward and 
1.7381Euro (SD0.8842) per patient in the internal care ward. Logically, the average daily 
cost per patient increases with its complexity (Table 3), but differences in average cost of  
therapy among both departments were not statistically significant.  
 
Analysis of drug interactions and likelihood of errors  
Because no statistically significant differences in prescribing practice concerning the 
complexity of therapy, frequency of prescribed cardiovascular medicines, and 
pharmacotherapy cost were found, we reviewed all prescribed combinations in both 
departments potentially risky for development of ADR due to literature evidences (Table 4). 
Combination of diuretics and B-blockers increased the risk of ventricular arrhythmia, digoxin 
and some diuretics could lead to toxicity or AV block, some combinations with diuretics and 
ACE inhibitors could change the microelement balance, and some are risky for bleeding. 
Combination among Heparin and Glyceryl trinitate could be considered as wrong because of 
their mutual antagonism. The efficacy of Heparin is actually decreased by Glyceryl trinitate. 
Another improper combination is acid acetylsalicylic + ramipril, which are also antagonists.  
 
Table 4. Identified risks associated with the prescribed combinations  
 
Risk Combinations 
Ventricular arrhythmia 
 
carvediol + furosemide 
carvediol + spironolacton 
bisoprolol + hydrochlorthiazide 
bisoprolol + spironolacton 
bisoprolol + furosemide 
AV block and 
bradycardia digoxin + bisoprolol 
Intoxication digoxin  + spironolacton 
Toxicity acid acetylsalicylic + hydrochlorthiazide 
Hyperkalaemia 
hydrochlorthiazide + ramipril 
furosemide + perindopril 
furosemide + ramipril 
heparin + ramipril 
heparin  + perindopril 
Hypokalaemia furosemide  + hydrochlorthiazide 
Bleeding heparin + clopidogel acenocoumarin + acid acetylsalicylic 
Antagonistic 
combinations 
heparin + glyceryl trinitate 
acid acetylsalicylic + ramipril 
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Summarising the risky combinations we evaluated their distribution in both departments in 
Table 5. No significant difference was observed (p>0.05).  
 
Table 5. Identified interactions and possible risks 
 
Type of interaction N of patients Share 
Intensive care 
ward 
Internal care 
ward t-test 
Ventricular 
arrhythmia 9 32.14% 2 7 
p>0.05 
AV block and 
bradycardia 1 3.57% 0 1 
Intoxication 1 3.57% 1 0 
Toxicity 5 17.86% 2 3 
Hyperkalaemia 5 17.86% 2 3 
Hypokalaemia 4 14.28% 2 2 
Bleeding 3 10.71% 2 1 
 
DISCUSSION 
We have focused on cardiology clinic for our study as the prescribing practice there is usually 
complex and lots of combinations are used which increase the risk of errors and/or DRP [16]. 
In addition there are intensive care patients that are in a higher risk for ADR development. 
Our analysis showed that the most frequent errors were concerning missing data in the 
prescriptions and they were corrected promptly. Despite of the high relative share of 
potentially risky combinations we did not find an evidence for any ADR reporting in the 
ward.  
 
Analysis of the prescriptions in both departments of Cardiology clinic in Medical 
University’s hospital confirmed the data from similar studies [16], showing that the hospital 
treatment of cardiovascular diseases is mainly a combined therapy, aimed at integrated 
approach to improvement of therapeutic outcomes and health status of patients by influencing 
the different pathogenetic mechanisms of the disease. Co-administration of two or more 
medicinal products may be useful and necessary when the combination is chosen correctly, 
prescribing patterns are observed and the risk of drug interactions and errors in administration 
are taken into account. We did not observe the difference in the combination therapy among 
both observed departments – intensive care and internal department that might be due to the 
short period of stay in the intensive care department. 
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Despite of the fact that the appearance of interactions and ADRs was not documented, the 
prescription of risky combinations needs to be limited, having in mind the high risk for 
patients with cardiovascular diseases, which often suffer from complications.  
 
Prevention of this problem is very important [9]. Managing drug interactions in hospitalized 
patients is challenging and different approaches have been implemented on a hospital level to 
cope with the potential drug interactions for the benefit of the patients and success of 
treatment – i.e. greater involvement of hospital pharmacists in drug prescribing and 
utilization, use of clinical pharmacists, computerized screening etc. [17-19]. We can 
recommend to the hospital manager educational and evaluation measures to be introduced for 
better recording of ADRs. 
 
CONCLUSIONS 
The possibility of drug related problems in the observed Cardiology clinic is high but no 
policy for ADRs recording have been found in place. There are no differences in the 
prescribing practice, cost and risk of drug related problems occurring in intensive care and 
intensive ward. The risk of prescribing error and/or interactions in the cardiology clinic 
requires special attention by the clinical and pharmacy staff. 
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